A5040290186- Complement system in diseases
- Systemic Lupus Erythematosus Research
- Renal Diseases and Glomerulopathies
- Adenosine and Purinergic Signaling
- Diabetes Treatment and Management
- CRISPR and Genetic Engineering
- Intracerebral and Subarachnoid Hemorrhage Research
- Chemical Reactions and Isotopes
- Erythropoietin and Anemia Treatment
- Blood groups and transfusion
- Transgenic Plants and Applications
- Toxin Mechanisms and Immunotoxins
- Radiopharmaceutical Chemistry and Applications
- Pharmacological Receptor Mechanisms and Effects
- Blood Coagulation and Thrombosis Mechanisms
- Neurological Complications and Syndromes
- COVID-19 Impact on Reproduction
- Platelet Disorders and Treatments
- Nicotinic Acetylcholine Receptors Study
- Cancer Treatment and Pharmacology
- SARS-CoV-2 and COVID-19 Research
- Dermatological and COVID-19 studies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Radioactive Decay and Measurement Techniques
- Erythrocyte Function and Pathophysiology
Johns Hopkins Medicine
2021-2024
Johns Hopkins University
2021-2024
Johns Hopkins Hospital
2024
Northeastern University
2020
Gordon Center for Medical Imaging
2020
Harvard University
2020
Massachusetts General Hospital
2020
University of California, Irvine
2016
Purpose: Using our chelate-free, heat-induced radiolabeling (HIR) method, we show that a wide range of metals, including those with radioactive isotopologues used for diagnostic imaging and radionuclide therapy, bind to the Feraheme (FH) nanoparticle (NP), drug approved treatment iron anemia. Material methods: FH NPs were heated (120°C) nonradioactive resulting metal-FH characterized by inductively coupled plasma mass spectrometry (ICP-MS), dynamic light scattering (DLS), r 1 2 relaxivities...
Abstract Complement-mediated hemolytic uremic syndrome (CM-HUS) is a thrombotic microangiopathy characterized by germline variants or acquired antibodies to complement proteins and regulators. Building upon our prior experience with the modified Ham (mHam) assay for ex vivo diagnosis of complementopathies, we have developed an array cell-based “biosensors’’ selective removal regulatory (CD55 CD59, CD46, combination thereof) in autonomously bioluminescent HEK293 cell line. These biosensors...